A Phase 1/2 interventional study of delandistrogene moxeparvovec and placebo in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 2 sites in United States. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 15th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 7 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 5 started in 2018.
This study's enrollment of 41 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer in DMD participants by measuring biological and clinical endpoints in three parts: two 48-week randomized, double-blinded, placebo-controlled periods (Part 1 and Part 2), and an open-label follow-up period (Part 3). Participants who are randomized to placebo in Part 1 will have the opportunity for treatment with delandistrogene moxeparvovec in Part 2.
In order to provide a uniform approach to monitoring long-term safety and efficacy in participants who received SRP-9001 in a clinical trial, the Sponsor has amended Study Completion for this study to occur at Week 130. Therefore, participants have transitioned and will complete the remainder of the Part 3 follow up visits in a long-term extension study, SRP-9001-305 (NCT05967351).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive delandistrogene moxeparvovec at Part 1 followed by matching placebo at Part 2 followed by an open-label extension at Part 3.
Genetic: delandistrogene moxeparvovec · Genetic: placebo
Participant will receive matching placebo at Part 1 followed by delandistrogene moxeparvovec at Part 2 followed by an open-label extension at Part 3.
Genetic: delandistrogene moxeparvovec · Genetic: placebo
Single IV infusion of delandistrogene moxeparvovec
Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
Single IV infusion of matching placebo
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by Western Blot. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
Time frame: Baseline, Week 12 (Part 1)
Change From Baseline at Week 48 in NSAA Total Score
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
Change From Baseline at Week 48 in Time to Rise From the Floor
This functional assessment was performed as a part of the NSAA and measures the time taken to rise from supine to standing. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
Change From Baseline at Week 48 in Time to Ascend 4 Steps
This functional assessment measures the time taken to climb 4 steps. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
Change From Baseline at Week 48 in Time of 10-meter Timed Test
This functional assessment measures the time needed to move 10 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
Change From Baseline at Week 48 in Time of 100-meter Timed Test
This functional assessment measures the time needed to move 100 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity
Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF fiber intensity. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment and reviewed by trained evaluators. An increase in IF fiber intensity (percent control) indicates increased delandistrogene moxeparvovec dystrophin expression, relative to non-dystrophic muscle (the control).
Time frame: Baseline, Week 12 (Part 1)
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)
Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment. The number of muscle fibers expressing dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates the number of muscle fibers with increased delandistrogene moxeparvovec dystrophin expression.
Time frame: Baseline, Week 12 (Part 1)
Participants Experiencing Adverse Events (AEs) Since Treatment With Delandistrogene Moxeparvovec
Participants experiencing AEs are reported based upon the time to AE onset after delandistrogene moxeparvovec infusion. Each analysis set includes data from both arms and is based upon the Delandistrogene Moxeparvovec-treated Population: all participants who were treated with delandistrogene moxeparvovec in Part 1 or Part 2. 'Delandistrogene Moxeparvovec switched over to Placebo' participants received delandistrogene moxeparvovec in Part 1, followed by placebo in Part 2. AEs experienced by participants during Parts 1, 2, and 3 of the study are reported. 'Placebo switched over to Delandistrogene Moxeparvovec' participants received placebo in Part 1, followed by delandistrogene moxeparvovec in Part 2. AEs experienced by participants during Parts 2 and 3 of the study are reported. No intervention was administered during Part 3. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Day 1 through final study visit (approximately 4.6 years)
Baseline NSAA Total Score by Age Group
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). This outcome measure presents only the baseline NSAA total score of the ITT population by the following age groups: 4-5 years old; 6-7 years old.
Time frame: Baseline
Change From Baseline at Week 48 in NSAA Total Score by Age Group
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
Time frame: Baseline, Week 48 (Part 1)
This was a 3-part clinical study of a single dose of delandistrogene moxeparvovec. Participants were randomized to receive delandistrogene moxeparvovec in one of two 48-week periods (Part 1 or Part 2) via a crossover study design. Part 3 was an open-label follow up.
| Milestone | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Started | 20 | 21 |
| Received at least 1 dose of study drug | 20 | 21 |
| Completed | 20 | 21 |
| Not completed | 0 | 0 |
| Milestone | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Started | 20 | 21 |
| Received at least 1 dose of study drug | 20 | 21 |
| Completed | 20 | 21 |
| Not completed | 0 | 0 |
| Milestone | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Started | 20 | 21 |
| Received at least 1 dose of study drug | 0 | 0 |
| Completed | 17 | 19 |
| Not completed | 3 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by Western Blot. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
| percent normal | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Baseline | 4.23 ± 6.83 | 1.91 ± 1.28 |
| Change from Baseline | 23.82 ± 39.76 | 0.14 ± 1.24 |
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
| score on a scale | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 48 in NSAA Total Score | 1.7 ± 0.6 | 0.9 ± 0.6 |
This functional assessment was performed as a part of the NSAA and measures the time taken to rise from supine to standing. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
| second | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 48 in Time to Rise From the Floor | -0.15 ± 0.25 | 0.35 ± 0.23 |
This functional assessment measures the time taken to climb 4 steps. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
| second | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 48 in Time to Ascend 4 Steps | 0.17 ± 0.26 | 0.03 ± 0.26 |
This functional assessment measures the time needed to move 10 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
| second | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 48 in Time of 10-meter Timed Test | 0.59 ± 0.20 | 0.10 ± 0.19 |
This functional assessment measures the time needed to move 100 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.
| second | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 48 in Time of 100-meter Timed Test | 4.29 ± 3.92 | 6.28 ± 3.83 |
Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF fiber intensity. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment and reviewed by trained evaluators. An increase in IF fiber intensity (percent control) indicates increased delandistrogene moxeparvovec dystrophin expression, relative to non-dystrophic muscle (the control).
| fiber intensity percent control | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity | 0.06 ± 0.11 | 0.00 ± 0.02 |
Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment. The number of muscle fibers expressing dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates the number of muscle fibers with increased delandistrogene moxeparvovec dystrophin expression.
| percent dystrophin positive fibers | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF) | 23.88 ± 25.58 | 5.09 ± 12.96 |
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). This outcome measure presents only the baseline NSAA total score of the ITT population by the following age groups: 4-5 years old; 6-7 years old.
| score on a scale | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Age Group: 4-5 years old | 20.1 ± 1.9 | 20.4 ± 2.7 |
| Age Group: 6-7 years old | 19.6 ± 4.1 | 24.0 ± 2.9 |
The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.
| score on a scale | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|
| Age Group: 4-5 years old | 4.3 ± 0.6 | 1.9 ± 0.6 |
| Age Group: 6-7 years old | -0.2 ± 0.7 | 0.5 ± 0.7 |
Participants experiencing AEs are reported based upon the time to AE onset after delandistrogene moxeparvovec infusion. Each analysis set includes data from both arms and is based upon the Delandistrogene Moxeparvovec-treated Population: all participants who were treated with delandistrogene moxeparvovec in Part 1 or Part 2. 'Delandistrogene Moxeparvovec switched over to Placebo' participants received delandistrogene moxeparvovec in Part 1, followed by placebo in Part 2. AEs experienced by participants during Parts 1, 2, and 3 of the study are reported. 'Placebo switched over to Delandistrogene Moxeparvovec' participants received placebo in Part 1, followed by delandistrogene moxeparvovec in Part 2. AEs experienced by participants during Parts 2 and 3 of the study are reported. No intervention was administered during Part 3. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| Participants | Less Than 1 Year After Delandistrogene Moxeparvovec Infusion | 1 to 2 Years After Delandistrogene Moxeparvovec Infusion | 2 to 3 Years After Delandistrogene Moxeparvovec Infusion | 3 to 4 Years After Delandistrogene Moxeparvovec Infusion | More Than 4 Years After Delandistrogene Moxeparvovec Infusion |
|---|---|---|---|---|---|
| Treatment-emergent AE (TEAE) | 41 | 37 | 33 | 17 | 3 |
| Serious AE (SAE) | 5 | 1 | 2 | 0 | 0 |
| Treatment-related TEAE | 37 | 2 | 1 | 0 | 0 |
| Treatment-related SAE | 3 | 0 | 0 | 0 | 0 |
| Any AE leading to study discontinuation | 0 | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 through final study visit (approximately 4.6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Delandistrogene Moxeparvovec | 0/20 (0%) | 3/20 (15%) | 20/20 (100%) |
| Part 1: Placebo | 0/21 (0%) | 2/21 (9.5%) | 21/21 (100%) |
| Part 2: Delandistrogene Moxeparvovec Switched Over to Placebo | 0/20 (0%) | 2/20 (10%) | 20/20 (100%) |
| Part 2: Placebo Switched Over to Delandistrogene Moxeparvovec | 0/21 (0%) | 1/21 (4.8%) | 21/21 (100%) |
| Part 3: Delandistrogene Moxeparvovec Switched Over to Placebo | 0/20 (0%) | 0/20 (0%) | 18/20 (90%) |
| Part 3: Placebo Switched Over to Delandistrogene Moxeparvovec | 0/21 (0%) | 2/21 (9.5%) | 19/21 (90.5%) |
| Event | Part 1: Delandistrogene Moxeparvovec | Part 1: Placebo | Part 2: Delandistrogene Moxeparvovec Switched Over to Placebo | Part 2: Placebo Switched Over to Delandistrogene Moxeparvovec | Part 3: Delandistrogene Moxeparvovec Switched Over to Placebo | Part 3: Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|---|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 2/20 | 1/21 | 0/20 | 0/21 | 0/20 | 1/21 |
| Femur fractureInjury, poisoning and procedural complications | 0/20 | 0/21 | 2/20 | 0/21 | 0/20 | 1/21 |
| Liver injuryHepatobiliary disorders | 1/20 | 0/21 | 0/20 | 0/21 | 0/20 | 0/21 |
| HypertransaminasaemiaHepatobiliary disorders | 1/20 | 0/21 | 0/20 | 0/21 | 0/20 | 0/21 |
| Humerus fractureInjury, poisoning and procedural complications | 0/20 | 1/21 | 0/20 | 0/21 | 0/20 | 0/21 |
| AppendicitisInfections and infestations | 0/20 | 0/21 | 0/20 | 1/21 | 0/20 | 0/21 |
| Event | Part 1: Delandistrogene Moxeparvovec | Part 1: Placebo | Part 2: Delandistrogene Moxeparvovec Switched Over to Placebo | Part 2: Placebo Switched Over to Delandistrogene Moxeparvovec | Part 3: Delandistrogene Moxeparvovec Switched Over to Placebo | Part 3: Placebo Switched Over to Delandistrogene Moxeparvovec |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 13/20 | 7/21 | 0/20 | 16/21 | 1/20 | 3/21 |
| Decreased appetiteMetabolism and nutrition disorders | 8/20 | 0/21 | 1/20 | 15/21 | 0/20 | 0/21 |
| Upper respiratory tract infectionInfections and infestations | 13/20 | 13/21 | 8/20 | 7/21 | 9/20 | 9/21 |
| NauseaGastrointestinal disorders | 7/20 | 2/21 | 2/20 | 11/21 | 0/20 | 0/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/20 | 6/21 | 3/20 | 1/21 | 2/20 | 4/21 |
| COVID-19Infections and infestations | 0/20 | 0/21 | 0/20 | 2/21 | 9/20 | 9/21 |
| Viral infectionInfections and infestations | 8/20 | 9/21 | 3/20 | 0/21 | 2/20 | 3/21 |
| Procedural painInjury, poisoning and procedural complications | 5/20 | 7/21 | 6/20 | 9/21 | 0/20 | 2/21 |
| IrritabilityPsychiatric disorders | 3/20 | 1/21 | 5/20 | 9/21 | 1/20 | 2/21 |
| Abdominal pain upperGastrointestinal disorders | 6/20 | 4/21 | 2/20 | 8/21 | 0/20 | 0/21 |
| Age, Continuous(years) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Mean | 6.29 ± 1.19 | 6.24 ± 1.13 | 6.27 ± 1.15 |
| Age, Customized(Participants) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 20 | 21 | 41 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 20 | 21 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 19 | 16 | 35 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 13 | 17 | 30 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 6 |
| North Star Ambulatory Assessment (NSAA) Group(Participants) | Delandistrogene Moxeparvovec Switched Over to Placebo | Placebo Switched Over to Delandistrogene Moxeparvovec | Total |
|---|---|---|---|
| NSAA baseline total score ≥ median score | 8 | 15 | 23 |
| NSAA baseline total score < median score | 12 | 6 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Dec 2020, 24 months.
Results were first posted in Sep 2023, 2 years 9 months after primary completion. A results delay was requested in Dec 2021.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →